{"product_id":"qdel-bcg-matrix","title":"(QDEL) QuidelOrtho Corporation BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis QuidelOrtho Corporation BCG Matrix helps you see how the company’s products or business units fit into Stars, Cash Cows, Question Marks, and Dogs, making it useful for strategy, portfolio review, and investment analysis. The page already shows a real preview of the actual report content, so you can review the format before buying. Purchase the full version to get the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePoint-of-care respiratory menu\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePoint-of-care respiratory menu is QuidelOrtho Corporation’s clearest Star in BCG terms. Used in medical offices, urgent care centers, retail clinics, and pharmacies, it fits recurring flu, RSV, and strep demand, which stays seasonal but durable across 2025. This category supports faster repeat testing and is the strongest growth pocket in QuidelOrtho’s rapid-testing portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCLIA-waived Sofia platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe CLIA-waived Sofia platform fits outpatient care because it delivers near-patient results in about 15 minutes and is built for high-volume, same-visit decisions. The U.S. has over 300,000 CLIA-waived sites, so broad access supports share. QuidelOrtho Corporation still needs more menu expansion and steady promotion to defend this franchise.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRespiratory combo assays\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRespiratory combo assays are a Star for QuidelOrtho Corporation because one test can detect COVID-19, influenza A\/B, and RSV, which fits the shift from one-virus pandemic testing to multi-pathogen respiratory care. In the 2025–2026 respiratory season, that 3-in-1 model supports steadier volume than single-disease tests, since providers still need fast triage across three major viruses. For QuidelOrtho Corporation, this keeps the category high-activity and less tied to one infection cycle.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUrgent-care infectious disease tests\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUrgent-care infectious disease tests are a Star for QuidelOrtho Corporation: this fast-cycle channel drives repeat use, not one-off demand. Its rapid assays support same-visit decisions for flu, RSV, and strep, helping clinics test and treat before patients leave.\u003c\/p\u003e\n\u003cp\u003eQuidelOrtho reported about $2.8 billion in 2024 revenue, and urgent care can keep placements sticky because each site needs steady cartridge and analyzer replenishment. That makes the channel more scalable than single-sale lab deals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFast same-visit diagnosis\u003c\/li\u003e\n\u003cli\u003eRepeat cartridge demand\u003c\/li\u003e\n\u003cli\u003eSticky clinic placements\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRetail pharmacy rapid diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRetail pharmacy rapid diagnostics is a Star for QuidelOrtho Corporation because it keeps high-traffic, fast-turn tests in front of consumers and clinicians. Pharmacy and retail clinic testing stayed important after COVID-19, and rapid respiratory tests still win on speed and convenience, which supports repeat use and broad menu visibility.\u003c\/p\u003e\n\u003cp\u003eThis channel also helps QuidelOrtho protect share in flu, RSV, and COVID workflows, where point-of-care results can drive same-visit decisions. It is a low-friction route to keep brands visible at the shelf and in clinic.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFast results drive repeat demand\u003c\/li\u003e\n\u003cli\u003ePost-COVID use stayed structurally higher\u003c\/li\u003e\n\u003cli\u003eSupports menu breadth and visibility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuidelOrtho’s Rapid Tests Power Outpatient Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuidelOrtho Corporation’s Stars are point-of-care respiratory and combo tests, led by Sofia and multi-pathogen assays. They fit the 2025–2026 season because flu, RSV, and COVID testing stay high-use in outpatient care, where fast same-visit decisions matter. Over 300,000 CLIA-waived U.S. sites support scale, and about $2.8 billion 2024 revenue shows the base is still large.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSofia\u003c\/td\u003e\n\u003ctd\u003eNear-patient rapid care\u003c\/td\u003e\n\u003ctd\u003e15 min\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCLIA-waived sites\u003c\/td\u003e\n\u003ctd\u003eWide access\u003c\/td\u003e\n\u003ctd\u003e300,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQuidelOrtho Corporation\u003c\/td\u003e\n\u003ctd\u003eRevenue base\u003c\/td\u003e\n\u003ctd\u003e$2.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuidelOrtho BCG Matrix: maps product lines into Stars, Cash Cows, Question Marks, and Dogs for clear invest, hold, or divest decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuick BCG snapshot for QuidelOrtho to pinpoint growth, cash cows, and drag—fast strategic clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuidelOrtho Corporation Reference Sources provide a credible audit trail that strengthens trust and speeds smarter decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVITROS chemistry systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn fiscal 2025, VITROS chemistry systems stayed a Cash Cow for QuidelOrtho Corporation because the Labs division sells mature clinical chemistry instruments plus recurring tests. Each installed analyzer keeps driving reagent pull-through, so utilization matters more than new unit growth. That steady, repeat demand makes the chemistry menu a classic cash generator.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVITROS immunoassay menu\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVITROS immunoassay menu fits a Cash Cow because immunoassay is a mature, high-volume lab segment that hospitals and reference labs run every day. QuidelOrtho can keep serving steady routine demand with lower support costs than newer platforms, so the product line can throw off dependable cash. In a market where volume matters more than rapid growth, recurring assay use is the key driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTransfusion medicine compatibility testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQuidelOrtho Corporation’s transfusion medicine compatibility testing is a cash cow: it sits in a highly regulated blood-bank market with long instrument replacement cycles and recurring demand for cards, reagents, and other consumables. These installed systems help protect blood safety and donor-recipient matching, so labs keep using them even in slow growth periods. That mix usually means steady margin and predictable cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBlood and plasma donor screening\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBlood and plasma donor screening is a core, non-discretionary step in the supply chain, since every donation must be tested before use. WHO says about 118.5 million blood donations are collected globally each year, and that volume is steady rather than fast-growing, which fits a Cash Cow profile for QuidelOrtho Corporation.\u003c\/p\u003e\n\u003cp\u003eThe work is operationally critical, recurring, and driven by installed testing workflows, so demand tends to track donation activity more than market hype. That usually supports stable reagent pull-through and cash generation, especially in large, regulated blood-bank and plasma-center networks.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEssential screening, not optional spend\u003c\/li\u003e\n\u003cli\u003eSteady donation-linked test volumes\u003c\/li\u003e\n\u003cli\u003eRecurring consumables support cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInstalled-base service and consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn FY2025, QuidelOrtho Corporation’s installed-base service and consumables stayed a cash cow because labs must keep buying reagents, controls, calibrators, and maintenance after analyzer placement. That repeat demand is low-capex and supports steadier cash flow than new-system sales; it also fits a business that reported about $2.8 billion in annual revenue in FY2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRepeat sales follow each analyzer install.\u003c\/li\u003e\n\u003cli\u003eConsumables need regular replenishment.\u003c\/li\u003e\n\u003cli\u003eService supports predictable cash flow.\u003c\/li\u003e\n\u003cli\u003eGrowth needs stay relatively low.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuidelOrtho’s Cash Cows: Recurring Revenue from Installed Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn FY2025, QuidelOrtho Corporation’s cash cows were mature, installed-base products that keep selling reagents, controls, and service after placement. VITROS chemistry, VITROS immunoassay, transfusion medicine, and donor screening all fit this pattern because demand is recurring, regulated, and tied to daily lab use.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash cow\u003c\/th\u003e\n\u003cth\u003eWhy it stays steady\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVITROS chemistry\u003c\/td\u003e\n\u003ctd\u003eRecurring reagent pull-through\u003c\/td\u003e\n\u003ctd\u003eInstalled analyzers drive repeat use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTransfusion medicine\u003c\/td\u003e\n\u003ctd\u003eLong replacement cycles\u003c\/td\u003e\n\u003ctd\u003eWHO: 118.5M blood donations a year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstalled base\u003c\/td\u003e\n\u003ctd\u003eService and consumables\u003c\/td\u003e\n\u003ctd\u003eQuidelOrtho revenue was about $2.8B in FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eQuidelOrtho Corporation Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe QuidelOrtho Corporation BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No demo pages or placeholder content—just the full, professionally formatted file. It’s ready to download, review, and use right away for strategy, analysis, or presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCOVID-19 antigen-only kits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQuidelOrtho Corporation’s COVID-19 antigen-only kits fit the Dogs bucket: single-disease demand has fallen hard since the pandemic peak, and 2024–2025 channel inventory and test utilization have normalized. The business now adds little growth, with 2024 net revenue at $2.77 billion, down from $2.84 billion in 2023. These SKUs look more like a low-growth holdover than a long-term growth engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCOVID-19 molecular-only tests\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCOVID-19 molecular-only tests fit a Dog in QuidelOrtho Corporation’s BCG Matrix because standalone SARS-CoV-2 demand has cooled and is no longer a high-growth lane. Respiratory panels now bundle flu, RSV, and COVID in one order, which cuts the need for COVID-only assays. That weakens pricing power and lowers strategic value versus broader multiplex testing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePandemic emergency-use products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePandemic emergency-use products are Dogs for QuidelOrtho Corporation because demand fades when routine testing and treatment pathways return. Their sales spike with outbreak waves, but that pattern is short-lived and does not support durable capital use. These products fit a weak long-term investment case.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLegacy at-home COVID tests\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegacy at-home COVID tests are a Dogs asset for QuidelOrtho Corporation: demand fell hard after the 2020–2022 surge, and retail replenishment is now well below peak levels. The category still exists, but repeat buying is limited, so growth and margin lift are weak.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePost-surge demand normalized\u003c\/li\u003e\n\u003cli\u003eRetail restocking stayed low\u003c\/li\u003e\n\u003cli\u003eCategory remains, but muted\u003c\/li\u003e\n\u003cli\u003eLow growth, low strategic priority\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eExcess COVID manufacturing capacity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eQuidelOrtho Corporation still carries COVID-era plant and equipment built for peak test demand, but that demand has fallen hard since the pandemic. When volumes drop, fixed costs like labor, depreciation, and maintenance stay in place, so excess capacity can weigh on margins instead of driving growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBuilt for surge, not steady demand\u003c\/li\u003e\n\u003cli\u003eFixed costs keep pressuring profit\u003c\/li\u003e\n\u003cli\u003eIdle capacity turns into a drag\u003c\/li\u003e\n\u003cli\u003eNeeds lower output or new uses\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuidelOrtho’s COVID-Only Tests Have Lost Their Growth Edge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs in QuidelOrtho Corporation are the COVID-only lines: demand normalized after the surge, and 2024 net revenue fell to $2.77 billion from $2.84 billion in 2023. These products have weak repeat use, low growth, and little pricing power, so they no longer justify heavy capital.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog area\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eCOVID-only tests\u003c\/td\u003e\n\u003ctd\u003eDemand cooled\u003c\/td\u003e\n\u003ctd\u003e2024 revenue $2.77B\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSavanna molecular platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSavanna is a Question Mark: a newer molecular platform with growth upside, but adoption is still early. QuidelOrtho reported 2024 net sales of $2.69 billion, while Savanna still needs more placements and a wider assay menu to prove scale. In a molecular testing market growing about 6%-8% a year, the platform can win share if utilization ramps fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSolana molecular system\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSolana stays a question mark in QuidelOrtho Corporation’s BCG Matrix because molecular diagnostics still has strong demand, but QuidelOrtho does not lead the field. It sits against larger peers with broader menus and deeper installed bases, so the platform has not yet built enough pull-through to shift toward star status. In 2025, the issue is less category growth and more competitive share capture and menu expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLyra PCR assay menu\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLyra PCR assay menu fits a Question Mark in QuidelOrtho Corporation’s BCG matrix: PCR assays serve high-value infectious disease workflows, but share is still being built in a crowded market led by Roche, Cepheid, and bioMérieux. Menu expansion is the main lever, because broader panels can lift utilization and help win placements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAmpliVue rapid molecular assays\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmpliVue rapid molecular assays sit in a growth niche, but they still look like a Question Mark for QuidelOrtho Corporation because scale is limited and the path to broader use is not proven. Adoption hinges on instrument placement, payer reimbursement, and how well the test fits clinic workflow. In a market where rapid molecular testing can cut turnaround to about 15 to 30 minutes, weak installed base can still cap share.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGrowth niche, but low scale.\u003c\/li\u003e\n\u003cli\u003eReimbursement drives uptake.\u003c\/li\u003e\n\u003cli\u003eWorkflow fit matters most.\u003c\/li\u003e\n\u003cli\u003eWithout placement, it stays a Question Mark.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNew molecular respiratory panels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNew molecular respiratory panels stay a Question Mark for QuidelOrtho Corporation: the category is still moving beyond COVID-19, so multi-pathogen panels can win share if the Company keeps pace on menus, instrument installs, and reimbursement. Success hinges on FDA clears and sales execution, not just assay quality.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGrowth depends on multi-pathogen demand.\u003c\/li\u003e\n\u003cli\u003eRegulatory wins are the key gate.\u003c\/li\u003e\n\u003cli\u003eCommercial follow-through decides share.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuidelOrtho’s Question Marks Need Share, Not Just Demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuidelOrtho Corporation’s Question Marks need share, not demand, to prove themselves. Savanna, Solana, Lyra PCR, AmpliVue, and new respiratory panels all sit in growing niches, but each is held back by limited placements, crowded rivals, and uneven reimbursement. With 2024 net sales of $2.69 billion, the Company still needs faster menu expansion and installed-base growth to move these products out of Question Mark status.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003eKey risk\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSavanna\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003eEarly adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLyra PCR\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003eCrowded market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234886361353,"sku":"qdel-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/qdel-bcg-matrix.webp?v=1785729486","url":"https:\/\/dcfanalyst.com\/products\/qdel-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}